198 related articles for article (PubMed ID: 24642868)
1. Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study.
Jensvoll H; Blix K; Brækkan SK; Hansen JB
PLoS One; 2014; 9(3):e92011. PubMed ID: 24642868
[TBL] [Abstract][Full Text] [Related]
2. White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø study.
Blix K; Jensvoll H; Brækkan SK; Hansen JB
PLoS One; 2013; 8(9):e73447. PubMed ID: 24023876
[TBL] [Abstract][Full Text] [Related]
3. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway.
Braekkan SK; Mathiesen EB; Njølstad I; Wilsgaard T; Størmer J; Hansen JB
J Thromb Haemost; 2010 Jan; 8(1):157-62. PubMed ID: 19496920
[TBL] [Abstract][Full Text] [Related]
4. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS).
Riedl J; Kaider A; Reitter EM; Marosi C; Jäger U; Schwarzinger I; Zielinski C; Pabinger I; Ay C
Thromb Haemost; 2014 Apr; 111(4):670-8. PubMed ID: 24306221
[TBL] [Abstract][Full Text] [Related]
5. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).
Simanek R; Vormittag R; Ay C; Alguel G; Dunkler D; Schwarzinger I; Steger G; Jaeger U; Zielinski C; Pabinger I
J Thromb Haemost; 2010 Jan; 8(1):114-20. PubMed ID: 19889150
[TBL] [Abstract][Full Text] [Related]
6. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism.
Gran OV; Braekkan SK; Paulsen B; Skille H; Rosendaal FR; Hansen JB
J Thromb Haemost; 2017 Jul; 15(7):1361-1367. PubMed ID: 28440069
[TBL] [Abstract][Full Text] [Related]
7. Platelet count and risk of major bleeding in venous thromboembolism.
Johnsen HS; Braekkan SK; Morelli VM; Hansen JB
Platelets; 2021 May; 32(4):444-452. PubMed ID: 32498591
[TBL] [Abstract][Full Text] [Related]
8. Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study.
Horvei LD; Braekkan SK; Smith EN; Solomon T; Hindberg K; Frazer KA; Rosendaal FR; Hansen JB
J Thromb Haemost; 2018 Jan; 16(1):83-89. PubMed ID: 29094466
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.
Thaler J; Ay C; Kaider A; Reitter EM; Haselböck J; Mannhalter C; Zielinski C; Marosi C; Pabinger I
Neuro Oncol; 2014 Dec; 16(12):1645-51. PubMed ID: 24987133
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of vitamin D are not associated with future risk of venous thromboembolism. The Tromsø Study.
Brodin E; Lerstad G; Grimnes G; Brækkan SK; Vik A; Brox J; Svartberg J; Jorde R; Hansen JB
Thromb Haemost; 2013 May; 109(5):885-90. PubMed ID: 23446951
[TBL] [Abstract][Full Text] [Related]
11. Hyperglycemia, assessed according to HbA1c , and future risk of venous thromboembolism: the Tromsø study.
Lerstad G; Brodin EE; Enga KF; Jorde R; Schirmer H; Njølstad I; Svartberg J; Braekkan SK; Hansen JB
J Thromb Haemost; 2014; 12(3):313-9. PubMed ID: 24382156
[TBL] [Abstract][Full Text] [Related]
12. Physical activity and risk of venous thromboembolism. The Tromso study.
Borch KH; Hansen-Krone I; Braekkan SK; Mathiesen EB; Njolstad I; Wilsgaard T; Hansen JB
Haematologica; 2010 Dec; 95(12):2088-94. PubMed ID: 20801904
[TBL] [Abstract][Full Text] [Related]
13. Thyroid function, as assessed by TSH, and future risk of venous thromboembolism: the Tromsø study.
Lerstad G; Enga KF; Jorde R; Brodin EE; Svartberg J; Brækkan SK; Hansen JB
Eur J Endocrinol; 2015 Jul; 173(1):83-90. PubMed ID: 25899580
[TBL] [Abstract][Full Text] [Related]
14. Arterial and venous thrombosis by high platelet count and high hematocrit: 108 521 individuals from the Copenhagen General Population Study.
Warny M; Helby J; Birgens HS; Bojesen SE; Nordestgaard BG
J Thromb Haemost; 2019 Nov; 17(11):1898-1911. PubMed ID: 31309714
[TBL] [Abstract][Full Text] [Related]
15. Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study.
Enga KF; Braekkan SK; Hansen-Krone IJ; le Cessie S; Rosendaal FR; Hansen JB
J Thromb Haemost; 2012 Oct; 10(10):2068-74. PubMed ID: 22882779
[TBL] [Abstract][Full Text] [Related]
16. Association of platelet activation markers with cancer-associated venous thromboembolism.
Riedl J; Hell L; Kaider A; Koder S; Marosi C; Zielinski C; Panzer S; Pabinger I; Ay C
Platelets; 2016; 27(1):80-5. PubMed ID: 25970326
[TBL] [Abstract][Full Text] [Related]
17. Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function--the Tromsø study.
Brodin EE; Brækkan SK; Vik A; Brox J; Hansen JB
Haematologica; 2012 Jul; 97(7):1008-13. PubMed ID: 22315498
[TBL] [Abstract][Full Text] [Related]
18. Carotid atherosclerosis predicts future myocardial infarction but not venous thromboembolism: the Tromso study.
Hald EM; Lijfering WM; Mathiesen EB; Johnsen SH; Løchen ML; Njølstad I; Wilsgaard T; Rosendaal FR; Brækkan SK; Hansen JB
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):226-30. PubMed ID: 24177328
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism increases the risk of atrial fibrillation: the Tromso study.
Hald EM; Enga KF; Løchen ML; Mathiesen EB; Njølstad I; Wilsgaard T; Braekkan SK; Hansen JB
J Am Heart Assoc; 2014 Jan; 3(1):e000483. PubMed ID: 24385452
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.
Ferroni P; Riondino S; Formica V; Cereda V; Tosetto L; La Farina F; Valente MG; Vergati M; Guadagni F; Roselli M
Int J Cancer; 2015 Mar; 136(5):1234-40. PubMed ID: 25042739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
